Related Experiment Video
Updated: May 16, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
Current loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and
Alessandra Cassio1, Annalisa Nicoletti, Angela Rizzello
1Department of Gynaecologic, Obstetric and Paediatric Sciences, S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. alessandra.cassio@unibo.it
Abstract:
Thyroid-stimulating hormone receptor (TSHR) loss-of-function (LOF) mutations lead to a wide spectrum of phenotypes, ranging from severe congenital hypothyroidism (CH) to mild euthyroid hyperthyrotropinemia. The degree of TSH resistance depends on the severity of the impairment of the receptor function caused by the mutation and on the number of mutated alleles In this review data about genotype-phenotype correlation and criteria for clinical work-up will be presented and discussed. Complete TSH resistance due to biallelic LOF TSHR mutations must be suspected in all patients with severe not syndromic CH and severe thyroid hypoplasia diagnosed at birth by neonatal screening. Partial forms of TSH resistance show a more heterogeneous hormonal and clinical pattern . In these cases TSH serum levels are above the upper limit of normal range for the age but with a very variable pattern, free thyroxine (T4) concentrations are within the normal range and thyroid size can be normal or hypoplastic at ultrasound scan. An early substitutive treatment with L-T4 must be mandatory in all patients with severe CH due to complete uncompensated TSH resistance diagnosed at birth by neonatal screening. The usefulness of substitutive treatment appears much more controversial inpatients with subclinical hypothyroidism due to partial TSH resistance in whom the increased TSH concentration should be able to compensate the mild functional impairment of the mutant receptor. Together with standard criteria we recommend also an accurate clinical work-up to select patients who are candidates for a LOF TSHR mutation.
Insights
Thyroid-stimulating hormone receptor (TSHR) loss-of-function mutations cause varied thyroid conditions. This review details genotype-phenotype correlations and clinical work-up criteria for TSHR mutations.
Area of Science:
- Endocrinology
- Genetics
- Molecular Biology
Background:
- Loss-of-function (LOF) mutations in the Thyroid-stimulating hormone receptor (TSHR) result in a spectrum of thyroid dysfunction.
- Phenotypes range from severe congenital hypothyroidism (CH) to mild euthyroid hyperthyrotropinemia, influenced by mutation severity and allele status.
Purpose of the Study:
- To review genotype-phenotype correlations in TSHR LOF mutations.
- To discuss criteria for clinical work-up and management of patients with TSHR mutations.
Main Methods:
- Review of existing data on TSHR mutations, genotype-phenotype correlations, and clinical presentations.
- Analysis of diagnostic criteria and treatment strategies for congenital and subclinical hypothyroidism related to TSHR function.
Main Results:
- Complete TSH resistance due to biallelic LOF TSHR mutations is suspected in severe CH and thyroid hypoplasia at birth.
- Partial TSH resistance presents with heterogeneous hormonal patterns, variable TSH levels, normal free T4, and variable thyroid size.
- Early L-T4 treatment is mandatory for severe CH due to complete TSH resistance.
Conclusions:
- Accurate genotype-phenotype correlation is crucial for diagnosing and managing TSHR LOF mutations.
- Clinical work-up should include genetic analysis to identify patients requiring intervention.
- Treatment decisions for partial TSH resistance require careful consideration due to controversial benefits.
Related Concept Videos
Hyperthyroidism II: Pathophysiology
Hyperthyroidism I: Introduction
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hypothyroidism II: Pathophysiology
Graves Disease II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
